Apr 25, 2016

Posted by in Biotech Stocks | 0 Comments

Stocks in Review: Sarepta Therapeutics Inc (NASDAQ:SRPT), Eleven Biotherapeutics Inc (NASDAQ:EBIO), Gilead Sciences Inc (NASDAQ:GILD)

Stocks in Review: Sarepta Therapeutics Inc (NASDAQ:SRPT), Eleven Biotherapeutics Inc (NASDAQ:EBIO), Gilead Sciences Inc (NASDAQ:GILD)

Sarepta Therapeutics Inc (NASDAQ:SRPT) surged +35.66% and ended at $14.95. The total traded volume was 31.32 million shares and market capitalization arrived at $926.18 million. The stock has a 52-week high price of $41.97 and its 52-week low was recorded at $10.20, while during last trade its minimum price was $11.10 and it gained the highest price of $15.70.

Sarepta Therapeutics Inc (NASDAQ:SRPT) on March 8, 2016 announced a long term plan to move all of the Company’s operations to Massachusetts, as part of a strategic plan to increase operational efficiency.

Over the course of the year, the Company plans to close their facility in Corvallis, Oregon, which primarily focused on early-stage research and research manufacturing. As part of the consolidation, research activities and some employees will transition to Sarepta facilities in Andover and Cambridge, Massachusetts.

The consolidation efforts are planned to occur in four waves – in May, October, November, and December of this year – with an estimated completion date of December 30, 2016.

Eleven Biotherapeutics Inc (NASDAQ:EBIO) reported the increase of +68.54% to close at $1.50 with the overall traded volume of 14.66 million shares. Its market capitalization on last close reached to $49.77 million. The company has the total of 19.68 million outstanding shares. Its intraday-low price was $0.93 and its hit its day’s highest price at $1.70.

Eleven Biotherapeutics Inc (NASDAQ:EBIO) on March 24, 2016 reported financial results for the fourth quarter and full year ended December 31, 2015.

Fourth Quarter and Year-End 2015 Financial Results:

  • Revenue: Revenue was $0.6 million for the three months ended December 31, 2015, compared to $0.4 million for the same period in 2014. Revenue was $1.0 million for the twelve months ended December 31, 2015, compared to $2.2 million for the same period in 2014.
  • R&D Expenses: Research and development expenses were $8.1 million for the three months ended December 31, 2015, compared to $5.3 million for the same period in 2014. This increase was primarily due to higher EBI-031 related development expenses partially offset by decreases in isunakinra related development expenses. Research and development expenses were $26.3 million for the twelve months ended December 31, 2015, compared to $26.7 million for the same period in 2014.
  • G&A Expenses: General and administrative expenses were $2.3 million for the three months ended December 31, 2015, compared to $2.2 million for the same period in 2014. General and administrative expenses were $9.9 million for the twelve months ended December 31, 2015, compared to $8.5 million for the same period in 2014.
  • Net Loss: Net loss applicable to common stockholders was $10.3 million, or $0.53 per share, for the three months ended December 31, 2015, compared to net loss applicable to common stockholders of $8.1 million, or $0.49 per share, for the same period in 2014. Net loss applicable to common stockholders was $33.5 million, or $1.76 per share, for the twelve months ended December 31, 2015, compared to net loss applicable to common stockholders of $34.7 million, or $2.37 per share, for the same period in 2014.
  • Cash and Cash Equivalents: Cash and cash equivalents were $36.1 million as of December 31, 2015. We believe that our current cash and cash equivalents, after giving effect to the $14.9 million prepayment to Silicon Valley Bank, will be sufficient to fund our operating expenses into the fourth quarter of 2016.

Gilead Sciences Inc (NASDAQ:GILD) moved up +0.19% to settle at $101.93. Its total traded volume during last trading session was 10.30 million shares. The overall market worth of this company is about $138.34 billion. The 52 week range of the stock remained $81.89 – $123.37, while its day’s lowest price was $100.50 and its hit its day’s highest price at $102.45. The beta of this stock currently stands at 1.03.

Gilead Sciences Inc (NASDAQ:GILD) on April 21, 2016 announced that its first quarter 2016 financial results will be released on Thursday, April 28, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the first quarter 2016 and provide a general business update.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

 

Comments are closed.